Richard Hargis – Employee Spotlight
Meet Richard Hargis – Sr. Director, Drug Product Manufacturing at Argonaut What’s a day in the life of a Drug Product Manufacturing Director at Argonaut?
Category: Drug Product Manufacturing
Optimizing Fill and Finish: Key Takeaways from the KBI and Argonaut Webinar
In the evolving landscape of biopharmaceutical manufacturing, optimizing fill and finish plays a critical role in ensuring product quality, regulatory compliance, and operational efficiency. C-level executives looking to streamline
Why Reshoring Pharmaceutical and Life Science Manufacturing to the U.S. Makes Business Sense
Choosing a Contract Manufacturing Partner as a Smart Strategy Reshoring Pharmaceutical and Life Science manufacturing to the U.S. over the next four years presents
Risk Evaluation in Pharmaceutical Fill/Finish Sourcing
Tips for Risk Evaluation in Pharmaceutical Fill/Finish Sourcing In this post we focus on the critical decision pharmaceutical companies face regarding their fill/finish needs: whether
Entrepreneurial Insights from Wayne Woodard, CEO of Argonaut Manufacturing Services on “Executing the Vision”
In the latest episode of Executing the Vision, Brad Hunter of Emerge Labs interviews Wayne Woodard, CEO of Argonaut Manufacturing Services, who shares his journey from
Abzena and Argonaut Partner to Offer Accelerated End-to-End Drug Development Support for Biopharmaceutical Companies
Biopharma gains a seamless transition from drug discovery through drug product manufacturing San Diego, CA, June 20, 2024 – Abzena, the leading end-to-end integrated contract
Five Advantages of Dual-Sourcing in Pharmaceutical Fill/Finish – Understanding the Imperative
How resilient is your manufacturing strategy in the face of potential disruptions to the pharmaceutical supply chain? As we navigate the complex landscape of aseptic
Strengthening Argonaut’s leadership position with investment from NewVale Capital and Telegraph Hill Partners
Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities with $45 Million Equity Investment from NewVale Capital and Telegraph Hill Partners Investment strengthens Argonaut’s
Navigating Uncharted Territories: Orphan Drug Aseptic Fill Finish, Clinical Trials, and the Impact of Advocacy
Supporting Orphan Drug Aseptic Fill Finish Rare diseases, also known as orphan diseases, are a group of diverse and often life-threatening conditions that collectively affect
Expanding in Combination Product and Drug Fill/Finish – Starting 2024 Strong
Why Your Biotech Contract Manufacturer is Expanding in Combination Product and Drug-Fill/Finish in 2024 Letter to Our Colleagues, from Founder/CEO Wayne Woodard, Argonaut Manufacturing Services